Brief: Paratek Pharmaceuticals Inc - Granted Zai Lab An Exclusive License To Develop, Manufacture And Commercialize Nuzyra In Greater China Territory
16/12/2021 16:50
Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS INC - GRANTED ZAI LAB AN EXCLUSIVE
LICENSE TO DEVELOP, MANUFACTURE AND COMMERCIALIZE NUZYRA IN
GREATER CHINA TERRITORY
* PARATEK PHARMACEUTICALS INC - PARATEK RETAINS ALL
REMAINING
GLOBAL RIGHTS OF NUZYRA
* PARATEK PHARMACEUTICALS INC - EARNED A $6 MILLION
MILESTONE
PAYMENT UPON NMPA APPROVAL OF NUZYRA
Source text for Eikon: ID:nGNX6D9XvR
Further company coverage: PRTK.O
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million